Unknown

Dataset Information

0

The PAK1-Stat3 Signaling Pathway Activates IL-6 Gene Transcription and Human Breast Cancer Stem Cell Formation.


ABSTRACT: Cancer stem cells (CSCs) have unique properties, including self-renewal, differentiation, and chemoresistance. In this study, we found that p21-activated kinase (PAK1) inhibitor (Group I, PAK inhibitor, IPA-3) and inactivator (ivermectin) treatments inhibit cell proliferation and that tumor growth of PAK1-knockout cells in a mouse model is significantly reduced. IPA-3 and ivermectin inhibit CSC formation. PAK1 physically interacts with Janus Kinase 2 (JAK2), and JAK2 inhibitor (TG101209) treatment inhibits mammosphere formation and reduces the nuclear PAK1 protein level. PAK1 interacts with signal transducer and activator of transcription 3 (Stat3), and PAK1 and Stat3 colocalize in the nucleus. We show through electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), and reporter assays that the PAK1/Stat3 complex binds to the IL-6 promoter and regulates the transcription of the IL-6 gene. Inhibition of PAK1 and JAK2 in mammospheres reduces the nuclear pStat3 and extracellular IL-6 levels. PAK1 inactivation inhibits CSC formation by decreasing pStat3 and extracellular IL-6 levels. Our results reveal that JAK2/PAK1 dysregulation inhibits the Stat3 signaling pathway and CSC formation, the PAK1/Stat3 complex regulates IL-6 gene expression, PAK1/Stat3 signaling regulates CSC formation, and PAK1 may be an important target for treating breast cancer.

SUBMITTER: Kim JH 

PROVIDER: S-EPMC6826853 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The PAK1-Stat3 Signaling Pathway Activates <i>IL-6</i> Gene Transcription and Human Breast Cancer Stem Cell Formation.

Kim Ji-Hyang JH   Choi Hack Sun HS   Kim Su-Lim SL   Lee Dong-Sun DS  

Cancers 20191010 10


Cancer stem cells (CSCs) have unique properties, including self-renewal, differentiation, and chemoresistance. In this study, we found that p21-activated kinase (PAK1) inhibitor (Group I, PAK inhibitor, IPA-3) and inactivator (ivermectin) treatments inhibit cell proliferation and that tumor growth of PAK1-knockout cells in a mouse model is significantly reduced. IPA-3 and ivermectin inhibit CSC formation. PAK1 physically interacts with Janus Kinase 2 (JAK2), and JAK2 inhibitor (TG101209) treatme  ...[more]

Similar Datasets

| S-EPMC8409285 | biostudies-literature
| S-EPMC10404139 | biostudies-literature
| S-EPMC3291810 | biostudies-literature
| S-EPMC9655455 | biostudies-literature
| S-EPMC4109796 | biostudies-literature
| S-EPMC8964978 | biostudies-literature
| S-EPMC5385639 | biostudies-literature
| S-EPMC4806911 | biostudies-literature
| S-EPMC4637890 | biostudies-literature
| S-EPMC7787750 | biostudies-literature